Recent

% | $
Quotes you view appear here for quick access.

Financial News From Zacks Small Cap Research

  • Second quarter (SANW) revenue was far higher than our forecast because DuPont/Pioneer Seed  had requested that seed be delivered in December 2015 rather than January 2016 and S&W Seed was able to do this. Significant increases in available acreage, amounting to at least a 45% gain from  2015 calendar levels to generate …

  • APDN Exited Fiscal 1Q16 with a Strong Balance Sheet Zacks Small Cap Research - Thu, Feb 11, 2016 12:00 PM EST

    APDN ended the quarter with a strong balance sheet. In late November, APDN closed a registered direct offering of 2,500,000 shares of common stock at a price of $3.49 per share and its concurrent private placement of warrants to purchase 1,250,000 shares of common stock at a price of $.01 per warrant to certain institutional …

  • For the purpose of this research report, we will offer a business update and a review of notable events and milestones for InVivo Therapeutics (NVIV), a biomaterials and biotechnology company focused on technologies and treatments for acute and chronic spinal cord injury (SCI). InVivo Therapeutics was conducting an early …

  • SBOT: Potential Transformative Events in 2016 Zacks Small Cap Research - Thu, Feb 11, 2016 9:45 AM EST

    By Brian Marckx, CFA NASDAQ:SBOT Q1 2016 Financial Results Stellar Biotechnologies (NASDAQ:SBOT) reported financial results for their fiscal first quarter ending December 31 st .  Revenue jumped fairly ...

  • AMBS: Amarantus Eltoprazine Granted Orphan Drug Designation for PD-LID Zacks Small Cap Research - Wed, Feb 10, 2016 10:00 AM EST

    Eltoprazine is a small molecule 5HT1A/1B partial agonist in clinical development for the treatment of Parkinson's disease levodopa-induced dyskinesia (PD-LID), adult attention deficit hyperactivity disorder (ADHD) and Alzheimer’s aggression. Eltoprazine has been evaluated in over 680 human subjects to date, and has a well-established …

  • By Ian Gilson PhD, CFA NYSE:CTS Continued declines in the Chinese and European currencies impacted the fourth quarter. CTS (NYSE:CTS) has decided to repatriate overseas cash by paying itself a dividend ...

  • AEMD: More Shots on Goal for Hemopurifier, ESI Zacks Small Cap Research - Mon, Feb 8, 2016 9:45 AM EST

    By Brian Marckx, CFA NASDAQ:AEMD Fiscal Q3 2016 Financials, Operational Update  Aethlon Medical (NASDAQ:AEMD) reported financial results for their third quarter 2016 and provided an operational update.  ...

  • As far as we could tell there was no significant change in the discounting that occurs in the truck rental business, with Avis Budget Group (CAR $26.57) and Penske maintaining the status quo so the growth is mainly from truck count and, to a lesser extent, transaction growth. The greatest decline is during the fourth fiscal …

  • Cemtrex (CETX): Letter to Shareholders highlights achievements & opportunities Zacks Small Cap Research - Fri, Feb 5, 2016 10:05 AM EST

    This week, CEO Saagar Govil (CETX) issued his Annual Letter to Shareholders, in which he enumerated the company’s financial achievements, along with recent milestones realized. Cemtrex was uplisted from the OTC Exchange to the NASDAQ Capital Markets exchange. The Electronics Manufacturing Services Group experienced a …

  • INUV: Q4 Revenues Beat Expectations as Owned and Operated Segment Soars Zacks Small Cap Research - Thu, Feb 4, 2016 3:25 PM EST

    By Lisa Thompson NYSE:INUV Once again INUV (NYSE:INUV) beat revenue expectations by reporting revenues of $21.0 million versus $15.5 million last year up 36%. Fully diluted EPS was on target with expectations ...

  • CZO: Receives U.S. Patent for Enabling Pressurized Gas Expanded (PGX) Technology Zacks Small Cap Research - Thu, Feb 4, 2016 3:00 PM EST

    Ceapro’s core product base includes avenanthramides and beta glucan, two natural ingredients that are derived from oats that are currently being used in products such as Aveeno®, Burts Bees®, and Nexxus®.

  • CEMI: Zika Could Be Seamless Fit to CEMI's Fever Portfolio Zacks Small Cap Research - Tue, Feb 2, 2016 4:00 PM EST

    - As anticipated, Chembio (CEMI) is preparing to take the reins on detailing SURE CHECK HIV 1/2 in the U.S. after their distribution agreement with Alere Inc. (ALR) concludes on May 31st of this year.  Obviously Chembio knew this was coming so preparations have been in the works.  And CEMI already has already put infrastructure …

  • VNRX: More Positive Trial Data in Colon/Lung Cancers Zacks Small Cap Research - Tue, Feb 2, 2016 3:45 PM EST

    By Brian Marckx, CFA NYSE:VNRX UPDATES:  Prostate Trial Starts, Add’l Positive Data in Colon and Lung, ISO Cert, New Patents… It’s been a busy few months for VolitionRX (NYSE:VNRX) which, most importantly, ...

  • TENX: Patient Enrollment Accelerates in Phase 3 LEVO-CTS Zacks Small Cap Research - Tue, Feb 2, 2016 10:45 AM EST

    On February 1, 2016, Tenax Therapeutics, Inc. (TENX) provided an update for its ongoing Phase 3 LEVO-CTS trial for its lead product candidate, levosimendan for low cardiac output syndrome (LCOS) in cardiac surgery.

  • PBSV: Cash Flow Positive And Trading Below Book Value Zacks Small Cap Research - Mon, Feb 1, 2016 2:45 PM EST

    PBSV is looking to restart revenue growth and expects to put some of their $14.9M cash balance to work, noting in the 10-K that, “We are constantly realigning our business strategies to grow our business. As such, the Company management understands that planned infrastructure investments on human capital, new markets, …

  • MTNB: Cleared to Begin Phase 1 Study of MAT2501 Zacks Small Cap Research - Mon, Feb 1, 2016 11:00 AM EST

    On February 1, 2016, Matinas BioPharma Holdings, Inc. (MTNB) announced that the Investigational New Drug (IND) application for MAT2501 is now open and the company is authorized to initiate a Phase 1 clinical trial. The company is targeting MAT2501 for the treatment of non-tuberculous mycobacterium (NTM) infections. Matinas …

  • STLT Making Progress On Several Fronts Zacks Small Cap Research - Fri, Jan 29, 2016 1:15 PM EST

    By Brian Marckx, CFA OTC:STLT Lead Investigator Retained for Crotoxin Study, Balance Sheet Cleansing and Crotalin for Vet Market… Recent progress includes bringing on a renowned cancer specialist to lead ...

  • HNSN: Revolutionizing Physicians’ Capabilities With Robotics! Zacks Small Cap Research - Thu, Jan 28, 2016 5:00 PM EST

     Hansen Medical Inc. (HNSN) based in Mountain View, CA develops robotically steerable catheters for electrophysiological (EP) and peripheral vascular procedures. Stability is of prime importance in interventional procedures employing catheters since vessel walls are narrow and can be punctured easily. Robotic catheterization …

  • FMD: First Quarter Much Better Than Expected as Revenues Surge and Expenses Drop Zacks Small Cap Research - Thu, Jan 28, 2016 3:55 PM EST

    By Ann Heffron, CFA, CPA NYSE:FMD The First Marblehead Corporation (NYSE:FMD) reported its fiscal 2016 first quarter results for the period ended September 30, 2015, posting a net loss from continuing ...

  • SNS.V: Healthy Working Capital; Updated Resource Estimate Expected Zacks Small Cap Research - Thu, Jan 28, 2016 8:00 AM EST

    At the outset, contract agreements are being utilized to mine and process the sandstone resource at Sandtown, thereby proceeding with the development of the mine and generating cash flow without the need of directly investing capital in the purchase of mining or processing equipment. The company is in advanced negotiations …

  • SBOT: JV Offers Full Product Life Cycle Opportunity Zacks Small Cap Research - Tue, Jan 26, 2016 3:00 PM EST

    By Brian Marckx, CFA NASDAQ:SBOT SBOT JV with Neovacs: Opportunity to Participate in Manufacture and Sale of KLH-Based Vaccines  The January 20 th announcement that Stellar (NASDAQ:SBOT) and Neovacs S.A. ...

  • ATOS Sells Diagnostics and Becomes a Pure Play Biopharma Zacks Small Cap Research - Tue, Jan 26, 2016 1:25 PM EST

    Atossa received $50,000 on December 16, 2015, for the sale of the Common Stock and the right to receive, commencing in December 2016, monthly earn-out payments equal to 6% of gross revenue of the NRLBH, up to a total of $10,000,000. Atossa also has the right in four years to sell its Preferred Stock to the NRL Group for …

  • VIVMF: Upward Revision To Our Revenue Estimates Zacks Small Cap Research - Tue, Jan 26, 2016 1:10 PM EST

    By Brian Marckx, CFA OTC:VIVMF Asia Distribution:  Minimum Purchase Agreement Results in Upward Revisions to Our Revenue Estimates …  More highly positive news came this morning when Viveve (OTC:VIVMF) ...

  • On January 12, 2016, The Psychopharmacologic Drugs Advisory Committee (PDAC) of the U.S. Food and Drug Administration (FDA) voted 12-to-5 to recommend approval of Probuphine, the first long-acting, subdermal buprenorphine implant for the maintenance treatment of opioid addiction in stable patients receiving 8 mg or less …

  • By Ian Gilson, PhD, CFA NASDAQ:SANW S&W Seed (NASDAQ:SANW) is in the process of distributing non-transferable subscription rights to buy shares of stock for $4.15. The subscription rights may be exercised ...

  • CDTi : Spinel passes hot temperature testing. Zacks Small Cap Research - Tue, Jan 26, 2016 10:00 AM EST

    By Ian Gilson, PhD, CFA NASDAQ:CDTI Following the tests, announced on June 20, 2015, CDTi (NASDAQ:CDTI) has completed the next phase of testing of the Spinel catalyst. These tests are where the catalyst ...

  • MDGN: Pipeline Update. Affirming Buy Recommendation Zacks Small Cap Research - Fri, Jan 22, 2016 4:20 PM EST

    By Brian Marckx, CFA NYSE:MDGN Pipeline Update: TARGTEPO Stable >18 mo’s, Beta Thal Initiated, NFC-1 Data Expected Mid-2016…  Medgenics (NYSE:MDGN) continues to make substantive progress with moving ...

  • APHB: First Bacteriophage Candidate Enters the Clinic Zacks Small Cap Research - Wed, Jan 20, 2016 3:30 PM EST

    On January 20, 2016, AmpliPhi Biosciences Corp. (APHB) announced dosing of the first patient in the Phase 1 clinical trial of AB-SA01 for the treatment of Staphylococcus aureus infections in patients with chronic rhinosinusitis that have failed prior antibiotic therapy. Chronic rhinosinusitis (CRS) is one of the most common …

  • CDTi (CDTI) has announced the start of shipments of diesel oxidation catalysts (DOC) based on the SPGM technology to Panasonic Ecology systems. The company expects to reach a low million dollar run rate of sales to Panasonic Ecology by the end of the year.

  • PBIO Boosts Balance Sheet by PIPE Financing Zacks Small Cap Research - Wed, Jan 20, 2016 10:30 AM EST

    By Grant Zeng, CFA OTC:PBIO On Jan. 11, 2016, PBIO (OTC:PBIO) announced it has received $255,000 in gross proceeds from the fifth closing of its original $5 million Private Placement. This closing increased ...

  • MBVX: Secures Funding to Conduct Two Phase 1 Clinical Trials with HuMab-5B1 Zacks Small Cap Research - Tue, Jan 19, 2016 12:05 PM EST

    On January 19, 2016, MabVax Therapeutics Holdings, Inc. (MBVX) announced it closed on the first part of a financing agreement with Oxford Finance, LLC that will provide the company with up to $10 million in senior secured debt financing. A diagnostic assay using an antibody (CA19-9) raised to sLea is used worldwide to …

  • BMRA: Q2 Results, IBS Advisory Board Beefed Up Further Zacks Small Cap Research - Tue, Jan 19, 2016 12:00 PM EST

    Biomerica (BMRA) reported financial results for their fiscal second quarter ending November 2015.  Results, in both revenue and operating expenses, underperformed our estimates, although this was partially offset by relatively strong gross margin.  The majority of the $279k miss on revenue relates to much more tepid sales …

  • Resverlogix Corp. (RVX.TO) (RVXCF) began recruiting and dosing participants in the Phase 3 BETonMACE trial of apabetalone (RVX-208) in high-risk CVD patients with diabetes in November 2015. Dosing commenced two weeks after the opening of the first clinical trial sites.

  • MTST: Q3 Results, Initial Launch Expected in 2016 Zacks Small Cap Research - Mon, Jan 18, 2016 10:50 AM EST

    The state licensure and CLIA certification follows on the heels of studies validating the performance and accuracy of MTST’s fully automated MetaSite Breast assay.  In late August MTST announced the automated (i.e.

  • V.LMD: Misses Guidance But "Missed" Portion Pushed to Q1 2016 Zacks Small Cap Research - Mon, Jan 18, 2016 10:20 AM EST

    Other recent notable announcements were the approval for sale of VELscope VX in China and entry into a non-binding letter of intent to acquire 100% “of a growing and profitable technology company that would complement LED s existing businesses and provides a platform to assist LED in achieving its strategic, long-term business …

  • Midwest Energy Emissions (MEEC) – MATS Appears Intact with EPA’s Response Zacks Small Cap Research - Fri, Jan 15, 2016 10:00 AM EST

    The EPA has responded to the Supreme Court ruling in the Michigan et al v. EPA case. In late November 2015, the EPA proposed a notice supplementing the Mercury and Air Toxics Standards (MATS) which addresses the U.S. Supreme Court’s decision in Michigan et al v. EPA that was ruled upon on June 29, 2015. In the proposed …

  • PRTX: Two Clinical Trials Underway for PRTX-100 in Immune Thrombocytopenia Zacks Small Cap Research - Thu, Jan 14, 2016 12:00 PM EST

    On January 7, 2016, Protalex, Inc. (PRTX) filed form 10-Q with financial results for the second quarter of fiscal year 2016 that ended November 30, 2015. Subsequent to the end of the quarter, Protalex entered into a revised Credit Facility Agreement with Niobe Ventures, LLC, a limited liability company controlled by Arnold …

  • Oramed has developed a proprietary drug delivery technology POD™ (Protein Oral Delivery) to orally deliver peptides or proteins. The POD technology has been uniquely designed to prevent degradation of the protein in the gastrointestinal tract and enhance its absorption.

  • VIVMF: Revenue Remains On A Tear, Up 28% in Q4 Zacks Small Cap Research - Fri, Jan 8, 2016 10:45 AM EST

    By Brian Marckx, CFA OTC:VIVMF Q4 2015 Revenue Preannouncement:  Revenue On A Tear, Increases 28% in Q4, Follows Q3’s 8-Fold Jump…  Viveve Medical (OTC:VIVMF) preannounced expected revenue for Q4 of approximately ...

  • ZMS.V: Revenue Remains Sluggish Despite Accelerating Order Flow Zacks Small Cap Research - Thu, Jan 7, 2016 4:20 PM EST

    By Brian Marckx, CFA Financial Results, Operational Update ….   Zecotek (TSX:ZMS.V) (OTC:ZMSPF) reported financial results for their fiscal 2016 first quarter ending Oct 31, 2015.  Revenue, at just $150k, ...

  • BOTA: Initiating Coverage on Biota Pharma Zacks Small Cap Research - Wed, Jan 6, 2016 10:00 AM EST

    Lower respiratory tract infections are induced by various viruses. During the beginning of fall and spring seasons, these viruses contribute significantly to the incidence of viral respiratory tract infections.

  • SNGX has been busy in 2015 to advance its clinical programs. Zacks Small Cap Research - Tue, Jan 5, 2016 10:30 AM EST

    By Grant Zeng, CFA OBB:SNGX Soligenix (OBB:SNGX) has been busy in 2015 to advance its clinical programs.This article will summarize two key milestones Soligenix has achieved in 2015 and outline some key ...

  • FNJN Raising Estimates: New Mystery License Agreement Signed in Q4 2015 Zacks Small Cap Research - Mon, Jan 4, 2016 4:10 PM EST

    By Lisa Thompson NASDAQ:FNJN With the passage of time, and the Blue Coat win under its belt, Finjan (NASDAQ:FNJN) has begun to accelerate the rate of closing licensing deals. On the heels of its license ...

  • Zacks SCR Analysts Attending JP Morgan Healthcare Conferences Zacks Small Cap Research - Mon, Jan 4, 2016 4:00 PM EST

    Zacks SCR Analysts Attending JP Morgan Healthcare Conferences  Senior healthcare analysts from Zacks Small-Cap Research will be in San Francisco next week meeting with management of several small and micro-cap ...

  • LPCN: Lipocine Initiates Phase 2b Study of Once Daily Oral TRT Candidate, LPCN 1111 Zacks Small Cap Research - Mon, Jan 4, 2016 1:55 PM EST

    On January 4, 2016, Lipocine Inc. (LPCN) announced that the first patient has been dosed in its Phase 2b clinical study for LPCN 1111, a once daily oral testosterone replacement therapy (TRT) product candidate. As a reminder, LPCN 1111 is the next-generation oral TRT version of LPCN 1021 that has the potential for once …

  • CTSO: EAP Out, IDE/PMA Back On The Table Zacks Small Cap Research - Mon, Jan 4, 2016 10:45 AM EST

    As a reminder, in the spring of this year CTSO announced that that they were investigating the EAP pathway as a means to speed time to market of CytoSorb in the treatment of sepsis (and/or other critical care illnesses).  This would also be less costly upfront as compared to the traditional IDE/PMA route and allow for much …

  • On December 28, 2015, Pozen, Inc. (POZN) announced that the registration statement on form S-4 filed by Aralez Pharmaceuticals has been declared effective by the Securities and Exchange Commission (SEC) and that the company has set a shareholder meeting for February 2, 2016 to formally vote on the proposed merger with Tribute …

  • SNS.V: Select Sands reports 1st Fiscal Quarter Results: Very Healthy Working Capital Zacks Small Cap Research - Tue, Dec 22, 2015 11:30 AM EST

    On December 17, 2015, Select Sands (SNS.V) (CLICF) filed financial results for the first fiscal quarter ending October 31, 2015. Financing and Liquidity: During the first fiscal quarter, the company issued 6,725,000 shares, along with 6.725 million one-half share purchase warrants, in a private placement, which increased …

  • CPKF: Accelerating Growth in Merchant Card and Lending Operations Propels EPS Gains Zacks Small Cap Research - Tue, Dec 22, 2015 10:45 AM EST

    Results in 2014 exclude a $1.1 million pretax gain on the redemption of trust preferred securities ($780,000 or $0.19 per share on an aftertax basis). This feat was recently recognized by SNL Financial in a report that cited CPKF as one of only 20 banks in the country (and only two in Virginia) to increase dividends by …

  • CETX: Cemtrex Reports Fiscal 2015 Results; Top-line Continues to Grow Zacks Small Cap Research - Tue, Dec 22, 2015 10:30 AM EST

    By Steven Ralston, CFA NASDAQ:CETX Yesterday, Cemtrex (NASDAQ:CETX) filed financial results for fiscal 2015 ending September 30, 2015. Total revenues increased 19.4% from $47,653,114 to $56,887,389. Revenue ...

Next >>